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Abstract
Although there is no shortage of potential drug targets, there are only a handful known low-molecular-weight inhibitors of
protein-protein interactions (PPIs). One problem is that current efforts are dominated by low-yield high-throughput
screening, whose rigid framework is not suitable for the diverse chemotypes present in PPIs. Here, we developed a novel
pharmacophore-based interactive screening technology that builds on the role anchor residues, or deeply buried hot spots,
have in PPIs, and redesigns these entry points with anchor-biased virtual multicomponent reactions, delivering tens of
millions of readily synthesizable novel compounds. Application of this approach to the MDM2/p53 cancer target led to high
hit rates, resulting in a large and diverse set of confirmed inhibitors, and co-crystal structures validate the designed
compounds. Our unique open-access technology promises to expand chemical space and the exploration of the human
interactome by leveraging in-house small-scale assays and user-friendly chemistry to rationally design ligands for PPIs with
known structure.
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Introduction
Last year, the number of new drug applications (NDA) was just
18. This number poorly compares with more than 40 during the
late 90’s, i.e, before mapping the human genome. This reality
defies all expectations that genetic research and our understanding
of disease were going to lead to a new era of discoveries of novel
therapeutics. Indeed, a recent analysis has shown that more than
75% of protein research still focuses on the 10% of proteins that
were known before the human genome was mapped [1]. The
effect of this bias has a profound effect on drug discovery, as
exemplified by the popular kinase target [2]. Interestingly, the
preconception that research might have somehow identified the
most important proteins is also false. Instead, the origin for this
bias has been traced back to the availability of small molecular
weight probes for only a narrow set of targets [1]. To break this
vicious circle, a new approach that stops our dependence from old
compounds, and that benefits from the vast amount of information
we now have on protein interactions, their structures and related
diseases – sic system biology – is desperately needed.
The success of both high-throughput screening (HTS) and
virtual screening depends on the content of the screened
compound library. Since existing libraries are historically biased
towards previous drug discovery efforts, the success of screening is
highly correlated to traditional targets [2,3,4]. The latter explains
in part the low hit rate of HTS when targeting new classes of
proteins [3,5,6,7,8], whose chemotypes are poorly represented in
current libraries [9,10]. A promising alternative pathway is the
development of suitable chemical libraries that in combination
with structure-based virtual screening can significantly increase hit
rates to 20% or more [4,11,12]. The challenge, however, is how to
design large virtual selective compounds for a given target without
running into the lengthy multi-step chemical synthesis that can be
one of the most critical bottleneck to the chemical biology
paradigm. Equally importantly is also how to bring these abstract
constructs into a useful format that can leverage the ingenuity of a
researcher expert on a given PPI and small-scale in house assays
that today are mostly underutilized in the development of novel
chemical probes of protein function.
We present a general solution to this problem by virtually
designing chemically accessible compounds capable of targeting a
broad set of protein-protein interactions (PPIs), a major problem in
modern drug discovery [10]. Instead of focusing in virtual
compounds that are often difficult to synthesize, our pipeline
leverages the combinatorial chemistry of a database of known and
proven (‘‘one-pot’’) chemical reactions to significantly expand the
space of drug-like compounds [13]. Computational chemistry tools
allow us to bias the design of the small molecules to target key
anchor residues [14] for almost any protein-protein interaction
with known structure. Moreover, we developed AnchorQuery, a user-
friendly ‘‘google-like’’ technology capable of mining in seconds
millions-size novel libraries of screening-ready products to enable a
fast and inexpensive approach for pharmaceutical intervention of
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MDM2/p53 cancer target, resulting in the largest and most
diverse set of inhibitors to this interaction. Crystal structures of our
compounds demonstrate that anchor-bound docked models
significantly enhanced the quality of the predictions, strongly
supporting our interactive approach to drug design.
Results
Expanding chemical space using multi-component
reactions
Multi-component reaction chemistry (MCR) [15] is an efficient
‘‘one-step, one pot’’ class of reactions that yield highly complex,
drug-like and screening-ready products. Although not common in
existing compound libraries, MCR compounds are well repre-
sented among known small-molecule PPI inhibitors [16,17,18].
More importantly, MCR derived peptido-mimetic chemotypes
allow us to design compound libraries that include chemical
mimics of key amino acids important for molecular recognition
[19]. For instance, using 23 MCR chemistries and a curated set of
commercially available or easily accessible starting materials, we
have designed anchor-biased libraries of .5 million compounds
targeting phenylalanine, tyrosine, tryptophan and valine/leucine,
adding to more than 21 million compounds, where every
compound contains a chemical analog of the targeted amino acid
(see Methods). A diversity analysis that compares the 16 million
aromatic-biased compounds and the 17.5 million compounds of
the ZINC database [20] shown in Figure 1 confirms that these
MCR compounds encompass an untapped region of chemical
space that is a departure from historical targets, such as kinase
inhibitors, while amenable to PPI targets, such as the p53/MDM2
interaction. These libraries, which already match the number of
commercially available drug-like compounds (see http://anchor-
query.ccbb.pitt.edu/reactions/) are available for screening and
download.
Design of Anchor-biased libraries
The inclusion of amino acid analogs allows us to design libraries
for specific ‘‘druggable’’ sites. To leverage this feature, we benefit
from the growing structural information on protein-protein
interactions exemplified by the Protein Data Bank (PDB) and
the validated binding sites revealed by co-crystals of PPIs. The
physicochemical characteristics of these interfaces have so far
proven to be very challenging for drug discovery: contact surfaces
involved in protein–protein interactions are typically large (1,500–
3,000 A ˚ 2) and flat [21], and only a few success stories have been
reported (e.g., Bcl2 [22], (X)IAP [23], and p53/MDM2 [24]).
However, a common element of several of these compounds is
specific moieties that mimic amino acid side chains of the donor
protein that are found deeply buried in the acceptor protein.
These anchor motifs often play a critical role in molecular
recognition [14,25,26] by targeting relatively stable surface pockets
Figure 1. Representation of the chemical diversity of our multi-component reaction aromatic-biased libraries (different
chemotypes shown in different colors) relative to the ZINC database [20] (red dots) and four predicted ligands. The diversity
space is visualized by plotting the top two principal components of the OpenBabel FP2 (http://openbabel.org) fingerprints of 200,000 compounds
randomly selected from the 17.5-and-16 million compounds of ZINC and our aromatic-biased database, respectively. The PPI-biased compounds are
focused on a different region of chemical space than the historically-biased ZINC database. Indeed, a library of kinase inhibitors, some containing a
tryptophan analog, falls squarely in the space covered by ZINC, while inhibitors of p53/MDM2, including inhibitors without a tryptophan analog, are
located in the space covered by the new libraries. Four novel compounds from four distinct scaffolds are found to match anchors on the GP41 dimer
[38], IKK [39], IL-2 [40] and EphB2 [41] receptors. Complete reaction chemistries of the AnchorQuery libraries can be found at http://anchorquery.ccbb.
pitt.edu.
doi:10.1371/journal.pone.0032839.g001
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chains correlate with those that bury the largest amount of solvent
accessible surface area upon binding [14]. Online tools are
available to search the PDB for anchors [27], revealing thousands
of potential druggable protein-protein interactions that are
‘‘biased’’ to the known chemistry of these key residues. A PDB-
wide statistics (see Figure S1) shows that aromatics and leucine
are the most enriched class of anchors among all interface residues
in PPIs. Thus, our motivation for designing PPI-biased libraries of
compounds containing specific analogs of Phe, Tyr, Trp, or Leu/
Val residues, as a first step towards being able to selectively target
PPIs in the PDB.
AnchorQuery: the first web-based technology for rational
drug discovery
In parallel with the development of million-size anchor-biased
libraries, we have developed an anchor-oriented virtual screening
technology to facilitate the rational design of small molecule protein-
protein antagonists. The goal of virtual screening is to generate a
substantially reduced and enriched subset of compounds from a
virtual chemistry space. Similarity search methods, despite their
simplicity, have been shown to be remarkably effective [28], but
are less applicable when screening for PPI inhibitors since there
are few described active ligands. Docking, which positions and
scores ligands within the interaction interface, can also be effective
[29] and provides useful structural insight, but is computationally
demanding. Another approach is a pharmacophore search, an
established mechanism for virtual screening that matches essential
features of ligands with derived or predicted features of an
interaction (see review by Leach et al. [30]). Our method is a novel
implementation of all the above, where we integrate the similarity
of the protein ligand into our biased libraries, the efficient docking
of the anchor-analogs into the anchor of the PPI and the direct
matching of pharmacophores (i.e., hydrophobic, hydrogen bonds,
and aromatic rings) into the docked models.
The technology, referred to as AnchorQuery, performs an exact
pharmacophore search of anchor-oriented virtual libraries of
explicit conformations. The computational performance of most
pharmacophore search implementations is directly proportional to
the size of the database limiting the effective size of virtual
libraries. AnchorQuery pharmacophore search uses a specialized
spatial index [31] so that searches scale with the breadth and
complexity of the query, not the size of the database. Unlike
previous methods, AnchorQuery does not require a highly reduced
chemical space [32] nor is it limited to specific chemical scaffolds
[33].
AnchorQuery is provided as an open-access, full-featured web server
at http://anchorquery.ccbb.pitt.edu. The goal of this technology is
to maximize the involvement of experts in collaborative protein-
based chemical biology design projects. The tool is readily
available to researchers around the world, enabling large-scale
design and synthesis of novel compounds suitable to interfere
specific PPIs. Pharmacophore features are automatically identified
and can be edited within the graphical interface, shown in
Figure 2(a). Additional information and a user guide are
provided at the website. Anew searches of billion conformations
are computed in a matter of seconds (see, e.g., online Interactive
Examples: Il-2, Caspase9, GP41, Ikk, and EphB2). Screens can
further prune the number of hits by setting a maximum number
for hits per compound, pharmacophore matches, or molecular
weight. The list of hits satisfying the query is ranked according to
several possible criteria: pharmacophore matches, pharmacophore
RMSD, number of rotatable bonds, MCR scaffold or molecular
weight (MW). The user interface includes Jmol (http://jmol.org)
based visualization of pharmacophore aligned or energy mini-
mized hits. Given that a key goal is to fast track the development of
novel chemical probes, all 21+ million compounds are linked to
Figure 2. The p53/MDM2 protein-protein interaction and open-access AnchorQuery web interface. (a) A screenshot of the online
AnchorQuery software show a query pharmacophore for targeting the p53/MDM2 interface. Two hydrophobic features with a 1 A ˚ radius (green) are
extracted from the F19 and L25 amino acids of p53 while a Tryptophan analog pharmacophore feature (yellow), unique to AnchorQuery, matches the
indole fragment of tryptophan. (b) In the p53/MDM2 complex (PDB 1YCR) three residues (F19, W23, L25) of p53 (green sticks) are buried in MDM2
(yellow surface). Only the W23 pocket is apparent in the unbound structure (PDB 1Z1M), suggesting that W23 plays a major role in molecular
recognition.
doi:10.1371/journal.pone.0032839.g002
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the reaction of each hit.
Application to p53/MDM2
The tumor suppressor p53 and its negative regulator MDM2 is
one of the most intensely studied PPIs, with a small number of
potent small molecular weight antagonists [17,24,34]. The co-
crystal structure [35] reveals that Trp23 of p53 is the most buried
side chain on MDM2 and a natural site to validate our technology
(Figure 2(b)). Interestingly, the NMR structure of the unbound
receptor highlights both the plasticity of the binding interface and
the fact that the cavity of Trp23 is more stable than that of any
other buried group. The latter strongly supports a rational anchor-
based approach for developing PPI antagonists. An example of a
p53/MDM2 pharmacophore defined within AnchorQuery is shown
in Figure 2(a).
AnchorQuery has been validated as part of a drug discovery effort
targeting the anti-cancer p53/MDM2 PPI. As a proof of principle,
we screened compounds from a prototype library of 20 MCR
reactions (Table S1; see Methods). The iterative screening of
several variations of the core pharmacophores shown in
Figure 2(a) successfully identified a broad set of MCR-
antagonists representing different scaffolds and starting materials
(see Fig. 1). The screens employed a variety of designs that aimed
at filling the hydrophobic pockets, keeping a low molecular mass,
and, exploiting the diversity of scaffolds (see Discussion). We
synthesized and validated using fluorescence polarization and
NMR, 80 inhibitors (,60 mM binding activity) of p53/MDM2
that contain an indole tryptophan anchor analog (some com-
pounds were found in smaller targeted screenings [12,36]).
Additionally, we derived 13 MDM2 antagonists from a novel
acyclic scaffold that was highly enriched using the pharmacophore
shown in Figure 2(a) (see below). The identification of these active
compounds is a direct validation of the utility of AnchorQuery.
Refinement and validation of an AnchorQuery-based
virtual screen
To further demonstrate the potential of AnchorQuery to expedite
the discovery of novel compounds, we screened a Trp-biased
prototype library of 600,000 compounds (see Methods). Since the
library is virtual, compounds synthesized by the efficient MCR
chemistry often include slight variations relative to the predicted
hits due to availability (expense) and experience of the chemists
with the starting materials and reactions. Hence, for the analysis
presented here, we have seeded all our 93 active compounds into
our Trp-biased library. We screen this library using the
pharmacophores shown in Figure 2(a). In a few seconds, the
virtual search of all conformers (more than half a billion) led to an
enriched subset of docked compounds that recovered most of our
hits. In Figure 3(a), we keep the three lowest pharmacophore
RMSD conformational poses for each compound resulting in
77343 conformations (0.08% of the library conformations) of
34876 compounds (5.9% of the library compounds). The results
include 78.5% of the known inhibitors resulting in an enrichment
factor of more than 10-fold. The inset in Figure 3(a) shows the
inhibitor with the lowest pharmacophore RMSD. This compound
has a 20 mM binding affinity and belongs to a family of
compounds that include sub-micromolar inhibitors [12]. Note
that the visualization tool of AnchorQuery provides a straightforward
visual validation of the pharmacophore design, and allows the user
to rapidly identify scaffolds that are a good starting point for
rational modifications and/or to incorporate knowledge based
changes.
Since the main goal of AnchorQuery is the identification of PPI
antagonists starting points (i.e., ‘‘hits’’) by a rationally driven
iterative process, the actual structural refinement and scoring of
the virtual hits is left to the preference of the user [37]. Hence, the
utility permits the free download of the designed compounds and
their associated synthesis pathway for in-house optimization and
synthesis. The above notwithstanding, to demonstrate the
relationship between pharmacophore matching of docked ligands
and a physically-based scoring function, Figure 3 shows a multi-
step energy-based refinement and ranking of the results.
Figure 3(b) displays the re-ranking after a fast fixed-receptor
energy minimization (see Methods; without solvation) of the
AnchorQuery pharmacophore ranked compounds (Fig. 3(a)). This
secondary screening quickly identifies complexes with clashes (i.e.,
interaction energy .0) resulting in a substantial enrichment of
known actives in the top 5,000 compounds (an enrichment factor
of more than 50-fold relative to the full library). Moreover, we
verified that, after minimization, 89% of the computer generated
docked structures of validated inhibitors remain close to their
original pharmacophore aligned poses, suggesting that our fast and
exact docked alignments yield satisfactory low-resolution models
(see also Figure 4 and Figure S2). The best evidence that
AnchorQuery selects a meaningful set of compounds is shown in
Figure 3(c), where a detailed scoring function (see Methods) that
includes solvation effects places almost all our high-affinity
inhibitors in the top 150. A selection of the top scoring compounds
is shown in Figure 3(d). Remarkably, 9 of the top 10 chemically-
distinct compounds are validated inhibitors (see Table S2 for
dose-response curves). Compound 23 in this ranking, a novel
acyclic scaffold, led to the synthesis of 20 slight derivatives (the
exact cpd. 23 was not synthesized). A total of 13 compounds were
found to be active, six of which, including compounds 18 and 21,
are ranked in the top 50 of the virtual screen. One of the most
important benefits of screening anchor-enriched million-size
libraries is the rich structural diversity of our hits: inhibitors from
five different reaction classes are among the top 10 ranked
compounds.
New class of MDM2 inhibitors
Crystallization of MDM2 with AnchorQuery derived hits confirms
the efficiency and usefulness of our anchor-centered approach.
The two crystal structures in Figure 4 show that both the anchor
analog and the docked models superimpose well with the anchor
side chain of MDM2/p53 and crystal structures, respectively,
validating our premise that anchor binding sites are natural targets
for pharmaceutical intervention. Figure 4(a) is similar to
compound 1 of Figure 3 and it has the same scaffold as the hit
shown in the inset of Figure 3(a). However, one of the most
important and unique features of our approach is that it can
identify compounds based on multiple scaffolds (chemotypes).
Figure 4(b) shows the crystal structure of a new class of MDM2
inhibitors derived from hit 23 of AnchorQuery, elucidating the first
MDM2 antagonist based on an acyclic scaffold. It reveals that the
chloroindole ring of the inhibitor fills the tryptophan pocket of
MDM2 and is stabilized by hydrophobic interactions and the
hydrogen bonding with the L54-MDM2 carbonyl oxygen. The
isobutyl part of the inhibitor occupies the phenylalanine pocket
and keeps numerous hydrophobic interactions to MDM2. The
expanded scaffold of the new class of inhibitors allows conforma-
tional plasticity and promotes an unusual stacking interaction of
the compound’s phenyl ring with the H96-MDM2 side-chain.
This p-p interaction provides yet a new starting point for further
diversifying our search for novel classes of inhibitors.
Enabling Interactive Drug Discovery
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Due to the high costs of traditional high throughput screening
(HTS) approaches [3] and often complex hit optimization
chemistry, most academic researchers lack the infrastructure to
embark in drug discovery efforts. Furthermore, the rigid format of
HTS is not amenable to incorporate and take advantage of the
biological and/or chemical insight that might exist for a given
target. To leverage this know-how as well as in-house small-scale
assays often available to individual researchers, we have developed
AnchorQuery, the first web-based screening technology to rationally
scrutinize different sets of hot spots to select suitable chemical
probes of protein interactions for optimization and synthesis.
Our platform builds on the role anchor side chains, i.e., those
that bury a large amount of surface area in the acceptor protein,
have in PPIs. At the onset of the recognition process anchors target
Figure 3. Refinement and validation of an AnchorQuery-based virtual screen. Each active compound was annotated with the binding
affinity of the racemic mixture. The library (see Methods) was searched using the pharmacophore of Figure 2. (a) The position of active compounds
of three affinity classes (points and histogram) within the RMSD ranked AnchorQuery pharmacophore search results (red line). Pharmacophore RMSD
successfully extracts all the high affinity (sub-mM) known actives from the library. (b) A similar plot after fast minimization and pharmacophore
filtering. This step effectively identifies compounds with unresolvable steric and electrostatic clashes and provides a more efficient starting
configuration for the next minimization step. (c) After minimization using a Poisson-Boltzman solvent model, high-affinity compounds are noticeably
differentiated from low-affinity compounds. (d) A selection of the top ranked compounds from the screen belonging to seven different scaffolds.
Shown are the top ten ranked compounds, which include nine validated inhibitors, and five virtual compounds (15, 23, 54, 55, 59) selected to
highlight the diversity of the results. For the Ki data, compounds 3, 4, 7 are measured as racemic mixtures, and compounds 10, 18, 21, 141 are
measured as diastereomeric mixtures. Compound 23 was developed into a series of related compounds, including 18, 21, and 141, which is shown
crystallized in Figure 4.
doi:10.1371/journal.pone.0032839.g003
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these side chains to design small molecule inhibitors using fast and
efficient MCR chemistry. Contrary to traditional stepwise
multistep sequential synthesis, MCR assembles advanced starting
materials into a new product in a ‘‘one-pot’’ procedure thus saving
tremendous time and effort when testing the computational
hypotheses. This approach has led to the development of a broad
set of novel active inhibitors of MDM2 and p53 interactions, with
crystal structures (Fig. 4) confirming the benefits of targeting the
known chemistry of anchor side chains.
The success identifying compounds based on multiple scaffolds
for p53/MDM2 led us to significantly expand our prototype
library to maximize the potential benefits of this new PPI-biased
chemical space and virtual screening technology. Currently, a
curated set of 21 million virtual compounds amenable to targeting
any PPI with a tryptophan, tyrosine, phenylalanine or leucine/
valine anchor is online, and libraries mimicking other anchors are
under development. AnchorQuery provides a direct link to this
chemical space for the screening of any PPI that involves anchors
present in our library. Applying the new libraries to p53/MDM2
(see Interactive example in AnchorQuery) results in an enrichment of
the van Leusen scaffold of trisubstituted imidazoles. A straightfor-
ward change of the hydrophobic pharmacophores in Fig. 2(a),
Phe19 and Leu25, for aromatic ones leads to top hits ranked
by molecular weight that are almost identical (Fig. 4(a))t o
compounds recently shown by us [36] and researchers of
NOVARTIS (Boettcher A, et al. 3-Imidazoyl-indoles for the
treatment of proliferative diseases, WO 2008119741) to be highly
active. More generally, Figure 1 shows four virtual examples of
interesting targets: GP41 [38] and IKK [39] with a tryptophan
anchor, and IL-2 [40] and EphB2 [41] with anchors that can be
targeted with our phenylalanine-biased library. The minimized
compounds match the anchor (in yellow), predicting compounds
that recover the chemistry seen in the co-crystals. Moreover, the
server also specifies the synthesis pathway for all the compounds, a
unique feature relative to other fragment-based or virtual
screening technologies that are limited by chemical synthesis.
Despite the thousands of validated protein-protein interactions,
the pace of discovery of chemical probes that can dissect the role of
individual protein interactions in signaling pathways remains slow.
Besides technical barriers, a major shortcoming in these efforts is
the lack of synergy between mature disciplines like chemistry,
which seeks to develop molecules with ‘‘drug-like’’ properties, and
biology, which inquires about functional aspects of protein-protein
interactions. AnchorQuery is a real-time, user-friendly, open-access
technology that delivers more than 21 million chemically
synthesizable compounds to facilitate truly integrative and
interdisciplinary research. With little or no effort human insight
can be incorporated into virtual screening of a novel chemical
space to test assays and new discovery strategies of small molecular
weight probes of protein function.
Methods
Library Design
We created our prototype tryptophan-biased virtual library by
randomly drawing indole-containing compounds from a diverse
set of 20 multi-component reactions (see Table S1). A total of
54,000 reactions were performed using randomly chosen reactants
and ChemAxons REACTOR software (http://www.chemaxon.
com). OpenEye OMEGA (http://eyesopen.com/) was used with
the default settings to enumerate 591,227 stereoisomers and
generate 97.9 million conformations.
Our ultimate goal is to develop libraries for all meaningful
anchor amino acids. Based on our experience with the prototype
library, we have currently created larger anchor-oriented libraries
for phenylalanine, tyrosine, and tryptophan anchors. These
libraries are created from an expanded set of 23 MCR chemistries
and starting materials that are curated for affordability, diversity,
and synthesizability. Complete details of the reaction chemistry are
provided at http://anchorquery.ccbb.pitt.edu. We do not exhaus-
tively enumerate all stereoisomers of compounds, instead only
sampling stereoisomers around stereocenters that significantly
change the geometry of the resulting conformations. 100
conformations are generated with OMEGA with a RMS cutoff
of 0.7, resulting in roughly 6610
8 conformations per AA-based
MCR library.
An analysis of typical drug-like properties of the resulting MCR
libraries shows that 25% of the compounds follow all 4 of
Lipinski’s rules; 66% of the compounds follow 3 out of 4 Lipinski’s
rules; 38% of the compounds follow rule ‘‘Molecular Weight
bellow 500 g/mol’’; 59% of the compounds follow rule ‘‘Absolute
Figure 4. Two crystal structures of p53/MDM2 inhibitors validate the anchor-centric approach and docked models. In both structures
the indole anchor analog of tryptophan overlaps almost perfectly with W23 in p53 (shown in yellow sticks), when the receptors are aligned the
MDM2 structure in the co-crystal (PDB 1YCR). (a) The ligand (purple sticks) of PDB 3LBK has a very similar binding mode to the number one hit in our
virtual screen (orange sticks). (b) The crystal pose of the AnchorQuery derived compound (purple) with the predicted pose (green) also aligned very
well. The presence of a second ligand near the binding interface distorts the receptor shape relative to the receptor used for docking.
doi:10.1371/journal.pone.0032839.g004
Enabling Interactive Drug Discovery
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32839Value of Log P#5’’; 99% of the compounds follow rule
‘‘Hydrogen Bond Acceptor #10’’; 95% of the compounds follow
rule ‘‘Hydrogen Bond Donor #5’’; and, 58% of the compounds
have ‘‘rotatable bonds #10’’. However, we note that the concept
of ‘‘drug-like’’ compounds in the framework of PPIs is not yet
settled. Furthermore, AnchorQuery does not deliver optimized
compounds but rather starting points for optimization, and often
it is in this second stage that drug-like properties are developed.
Pharmacophore search
The pharmacophore features are identified using standard
SMARTS expressions (REF). The coordinates of a feature are
determined by averaging the coordinates of all atoms matched by the
SMARTS expression. The default set of pharmacophores includes
expressions to match hydrogen bond donors and acceptors, positive
and negative ions, aromatic rings, and hydrophobic regions (see also
[31]). Pharmacophore features of a conformation are represented in
the coordinate system defined by the anchor analog in the
compound. These anchor-oriented features are decomposed into
coordinate-frame triangles that are stored as exact coordinates in a
spatial index, a query pharmacophore is similarly decomposed into
triangles and the results of range queries on the spatial index are
reconstructed into an alignment of virtual compounds to the query
pharmacophore. The spatial index used by AnchorQuery is a custom
variant of the Pharmer KDB-tree [31], which supports the efficient
storage and retrieval of data indexed by spatial coordinates. This
choice of data structure is particularly well suited for performing
efficient range searches over point data that is stored on disk. Since all
AnchorQuery pharmacophore queries must contain an anchor
pharmacophore feature, the query features can also be represented
in an anchor-oriented coordinate system and identifying all
compounds that match a query feature is a simple range query in
the spatial index.
Secondary Screening
All energy minimization calculations are performed using the
Merck Molecular Force Field [42] with OpenEye szybki software
version 1.3.4. The results of AnchorQuery pharmacophore search are
first quickly minimized within a fixed receptor (PDB 1YCR) with no
solvent model and Coulomb electrostatics to eliminate ligand poses
that are sterically or electrostatically infeasible. Minimized confor-
mations are then filtered against the original pharmacophore. Only
conformations that have a pRMSD less than one and an energy
score less than zero are retained. The best scoring conformation is
than further optimized within a fixed receptor using Poisson-
Boltzman electrostatics. Again, minimized results that no longer
match the original pharmacophore query (.1.0 A ˚ pRMSD) are
filtered out. At the transition between each stage the number of
sampledconformationsisreducedtomatchtheavailablecomputing
resources (the top 3 pharmacophore RMSD conformations are
selected from the AnchorQuery results and the top conformation of
each stereoisomer is selected from the first energy minimization).
The screen shown in Figure 3 took less than 12 hours on a single
3.33 Ghz Core i7 975 workstation with 12 GB of RAM.
Chemical Synthesis
All chemicals were purchased from Aldrich, Fisher Scientific,
Acros Organics or Alfa Aesar and used as received.
1H- and
13C-
NMR spectra were recorded on a Bruker Avance II Ultrashield
Plus 600 at 600 and 150 MHz, respectively. Chemical shift values
are in ppm relative to residual solvent signal. Abbreviations used
are s=singlet, brs=broad singlet, d=doublet, brd=broad
doublet, m=multiplet; data in parenthesis are given in the
following order: multiplicity, number of protons and coupling
constants in Hz. Flash chromatography was performed with the
indicated solvent mixture on silica gel, MP Silitech 32–63 D, 60 A ˚,
Bodman. Thin layer chromatography was performed using
Whatmann flexible-backed TLC plates on aluminum with
fluorescence indicator. Compounds on TLC were visualized by
UV-detection. HPLC-MS measurements were done on a
Shimadzu prominence HPLC equipped with a dual wavelength
UV detector and an API 2000 LC-MS/MS system, Applied
Biosystems MDS SCIEX, (MS) using a Dionex Acclaim 120
column (C18, 3 mm, 120 A ˚, 2.16150 mm) using a mobile phase of
water and acetonitrile, both containing 0.1% acetic acid and the
following gradient: 5–90% acetonitrile in 7 min, injection volume:
5 mL, detection wavelength 254 nm. HRMS measurements were
performed at the Department of Chemistry, University of
Pittsburgh with a Waters/Micromass Q-Tof spectrometer. Details
of each chemical reaction can be found in the Methods S1.
Fluorescence polarization binding assays (FP)
All FP experiments were performed as described by Czarna et
al. [43] and are also described in the Methods S2.
Protein expression, purification, crystallization, data
collection and structure solution
See Methods S2.
Supporting Information
Figure S1 The distribution of the most deeply buried
anchor (blue) with at least one anchor residue (DSA-
SA.80s and .70% of SASA is buried), compared with
the relative frequency of each residue in proteins.
(TIFF)
Figure S2 Virtual docking poses of the compounds of
Figure 3(d). Compounds 1 and 141 are shown in Figure 4.
(TIFF)
Table S1 Multicomponent reactions used in the generation of a
tryptophan-biased library. These reactions, together with a set of
roughly 1000 commercially available starting materials, define a
theoretical chemical space of more than three trillion distinct
chemical compounds. Requiring at least one indole starting
material in each reaction yields as many as 190 billion compounds
containing a tryptophan mimic.
(DOC)
Table S2 Inhibition curves of inhibitors from Figure 3(d)
shown with rank and affinity.
(DOC)
Methods S1 Chemical Synthesis.
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Methods S2 Experimental Procedures and Supplemen-
tary References.
(DOC)
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